Biotechnology company Nuclera has extended its Series C financing to $87 million to advance antibody engineering. The financing round, led by Elevage Medical Technologies and Jonathan Milner, was extended by $12 million following earlier investment worth $75 million. The funding is set to support Nuclera’s development of eProtein discovery for full-format antibody expression, purification and binding validation. Expanding eProtein Discovery with antibody-specific capabilities represents a strategic step […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!